Suven Pharmaceuticals Ltd. (IN:COHANCE)
:COHANCE
Want to see IN:COHANCE full AI Analyst Report?
Top Page
Suven Pharmaceuticals Ltd.
(COHANCE)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹474.00
▼(-46.81% Downside)
Action:ReiteratedDate:04/28/26
The score is primarily supported by solid financial strength (healthy balance sheet and revenue growth) and constructive technical momentum (price above key moving averages with positive MACD). The main drag is valuation risk due to the very high P/E, which reduces the overall attractiveness despite decent fundamentals.
Positive Factors
Strong revenue growth
Sustained top-line expansion demonstrates growing demand for Suven's CDMO services and supports higher utilization of manufacturing capacity. Over a 2-6 month horizon this revenue momentum underpins reinvestment in capacity, strengthens customer credibility, and increases visibility into multi-stage program revenues.
Negative Factors
Weaker free cash flow
Reduced free cash flow constrains the firm's ability to self-fund expansion, return capital, or absorb project timing delays. Over months this pressure can force prioritization of capex or working capital, elevating execution risk on scaling projects and slowing reinvestment into high-return manufacturing capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained top-line expansion demonstrates growing demand for Suven's CDMO services and supports higher utilization of manufacturing capacity. Over a 2-6 month horizon this revenue momentum underpins reinvestment in capacity, strengthens customer credibility, and increases visibility into multi-stage program revenues.
Read all positive factors
Suven Pharmaceuticals Ltd. (COHANCE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹137.95B
Dividend YieldN/A
Average Volume (3M)116.47K
Price to Earnings (P/E)92.3
Beta (1Y)0.94
Revenue Growth95.66%
EPS Growth-46.88%
CountryIN
Employees1,193
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.97
Shares Outstanding382,567,140
10 Day Avg. Volume24,499
30 Day Avg. Volume116,469
Financial Highlights & Ratios
PEG Ratio-9.48
Price to Book (P/B)16.23
Price to Sales (P/S)23.00
P/FCF Ratio207.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.15
Revenue Forecast (FY)₹25.96B
Suven Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical company specializing in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company was formerly known as S...
How the Company Makes Money
Suven Pharmaceuticals primarily makes money through contract services (CDMO/CRAMS), where it is paid by other pharmaceutical and biotech companies to develop processes and manufacture small-molecule APIs and intermediates. Revenue is generated via...
Suven Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.14B | 11.98B | 10.51B | 13.40B | 13.20B | 10.10B |
| Gross Profit | 12.65B | 8.22B | 6.80B | 7.52B | 7.46B | 5.73B |
| EBITDA | 4.30B | 4.06B | 4.09B | 5.73B | 5.79B | 4.41B |
| Net Income | 2.48B | 2.68B | 3.00B | 4.11B | 4.54B | 3.62B |
Balance Sheet | ||||||
| Total Assets | 55.68B | 30.32B | 22.54B | 19.66B | 18.30B | 14.74B |
| Cash, Cash Equivalents and Short-Term Investments | 4.03B | 2.90B | 8.21B | 4.84B | 5.26B | 1.88B |
| Total Debt | 4.51B | 2.79B | 649.96M | 703.41M | 971.27M | 1.43B |
| Total Liabilities | 16.44B | 11.91B | 2.03B | 2.31B | 3.02B | 2.94B |
| Stockholders Equity | 37.88B | 16.97B | 20.51B | 17.35B | 15.27B | 11.81B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.32B | 3.07B | 1.65B | 2.55B | 2.73B |
| Operating Cash Flow | 2.61B | 2.88B | 3.58B | 4.51B | 3.30B | 3.83B |
| Investing Cash Flow | -1.94B | -2.55B | -3.62B | -1.95B | -1.36B | -3.11B |
| Financing Cash Flow | -828.50M | 33.20M | -138.02M | -2.36B | -1.56B | -765.53M |
Suven Pharmaceuticals Ltd. Technical Analysis
Neutral
891.10
Price Trends
319.63
Positive
411.51
Negative
661.00
Negative
Market Momentum
13.79
Negative
72.12
Negative
79.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:COHANCE, the sentiment is Neutral. The current price of 891.1 is above the 20-day moving average (MA) of 320.47, above the 50-day MA of 319.63, and above the 200-day MA of 661.00, indicating a neutral trend. The MACD of 13.79 indicates Negative momentum. The RSI at 72.12 is Negative, neither overbought nor oversold. The STOCH value of 79.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:COHANCE.
Suven Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹395.24B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
72 Outperform | ₹345.72B | 31.59 | ― | 1.04% | 14.78% | 13.41% | |
69 Neutral | ₹137.95B | 92.29 | ― | ― | 95.66% | -46.88% | |
66 Neutral | ₹601.13B | 59.42 | ― | 0.15% | 27.46% | 320.69% | |
63 Neutral | ₹566.20B | 91.56 | ― | 0.12% | 13.99% | -27.80% | |
53 Neutral | ₹648.51B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:COHANCE
Suven Pharmaceuticals Ltd.
494.15
-640.00
-56.43%
IN:AJANTPHARM
Ajanta Pharma Limited
2,754.90
20.50
0.75%
IN:BIOCON
Biocon Limited
362.80
44.43
13.96%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,404.95
1,024.14
74.17%
IN:IPCALAB
IPCA Laboratories Limited
1,539.10
148.13
10.65%
IN:LAURUSLABS
Laurus Labs Ltd.
1,090.40
474.00
76.90%
Suven Pharmaceuticals Ltd. Corporate Events
Cohance Lifesciences Says Volume Surge in Shares Is Market-Driven
Apr 12, 2026
Cohance Lifesciences has responded to a query from the National Stock Exchange of India regarding a significant increase in trading volumes in its shares. The company stated that there is no undisclosed information or pending announcement under SE...
Cohance Lifesciences Appoints Sisir K. Mishra as Company Secretary and Compliance Officer
Mar 30, 2026
Cohance Lifesciences has appointed Sisir K. Mishra as its Company Secretary, Compliance Officer and Key Managerial Personnel, effective April 9, 2026. The decision, approved by the board on March 30, 2026 following the Nomination and Remuneration ...
Cohance Lifesciences Grants 198,711 Stock Options Under ESOP 2023
Mar 13, 2026
Cohance Lifesciences has approved the grant of 198,711 stock options to eligible employees of the company and its subsidiaries under its Employee Stock Option Plan 2023. The options, which are compliant with SEBI’s share-based benefit regula...
Cohance Lifesciences to Engage Investors at IIFL and Kotak Conferences in February 2026
Feb 20, 2026
Cohance Lifesciences Limited has announced that its management will participate in the IIFL Entrepreneurial India Conference in Mumbai on February 25, 2026, and the Kotak Chasing Growth Conference on February 26, 2026, engaging in both group and o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.